The study examined the levels of alpha and gamma interferons in the blood of 313 patients with systemic lupus erythematosus using an ultrasensitive test that can measure even very low concentrations of these substances.[1] The results showed that interferon-alpha (IFN-α), but not interferon-gamma (IFN-γ), was significantly associated with inflammation and measures of disease activity such as the SLEDAI-2K and SLE-DAS indices.[1] IFN-α was also positively associated with acute phase reactants (C-reactive protein and interleukin-6) and with the presence of antinuclear antibodies.[1] Conversely, disease remission and low activity were negatively associated with IFN-α levels.[1] Levels of both interferons showed minimal associations with demographic characteristics and traditional cardiovascular risk factors.[1] The authors conclude that IFN-α could serve as a biomarker for monitoring treatment response and long-term outcomes in patients with SLE, emphasizing the need for further research in this area.